‼️ BREAKING: Sanofi (EPA:SASY) reported stronger-than-expected third-quarter results and raised its annual outlook, driven by robust Dupixent demand. Business EPS, excluding one-off charges, rose 22% to €3.55, beating estimates of €2.79, while sales climbed 16.2% to €14.44 billion. Dupixent sales surged nearly 35% to €5.7 billion, above consensus of roughly €5 billion, while new drug launches grew 31.4% to €1.4 billion, helping offset a 6.6% decline in vaccine sales to €3.2 billion.
